Merck and Moderna's mRNA vaccine became the first neoantigen cancer therapy to clear Phase 3 trials, outperforming Keytruda alone at preventing melanoma's return in 1,000+ patients.
FDA approval is next step.
@thelolgic.bsky.social
@thelolgic.bsky.socialMerck and Moderna's mRNA vaccine became the first neoantigen cancer therapy to clear Phase 3 trials, outperforming Keytruda alone at preventing melanoma's return in 1,000+ patients.
FDA approval is next step.
@melanomafocus.bsky.socialGood luck and thank you to everyone running the Great North Run tomorrow on behalf of Melanoma Focus! We are beyond grateful for your support! đź’™
@mrsholden2019.bsky.socialCan you help me rally this weekend?
I can't lose momentum or I risk falling even further behind.
I have my next appointment with my oncologist in 2 weeks - along with my next Signatera test.
Please share for me!
❤️
#Cancer #Stage4 #Melanoma #DermSky #CanSky #UniversalHealthcare #MedicareForAll
@fds3rd.bsky.social@fds.wsocial.eu@melanomafocus.bsky.socialGet moving for 5 weeks for the 5th most common cancer in the UK.
đź“… October 1st- November 5th 2026
⌚ 20, 35 or 50 hours of movement (you can also pick your own goal)
🏊‍♀️ Move anyway you like
👉 Register today: bit.ly/4gxAf7S
#melanoma #themelanomamovementchallenge #melanomafundraiser
(2/2)
@lgmudder.bsky.social
@northwell-journals.bsky.socialMolecular Medicine - Journal
Article in Press: Clinical transcriptomics towards a companion diagnostic framework for immunotherapy in cutaneous melanoma | #MolecularMedicine #Immunotherapy #Melanoma #Transcriptomics link.springer.com/article/10.1...
@wordquad.bsky.social#Moderna Co-Founder #BobLanger Is a Billionaire Again After Turning Down 20 High-Paying Job Offers
The @mit.edu co-founder wins big after the company’s #mRNA cancer vaccine, developed with Merck, hit its goals in a Phase 3 trial targeting #melanoma
@sigtrans-sttt.bsky.socialWhich noncanonical tumor antigens can be translated into T-cell targets?
EVA003 emerges as a #Melanoma-enriched antigen whose HLA-A*03:01-presented peptide is recognized by a natural TCR that directs melanoma cell killing.
#STTT #OpenAccess: doi.org/10.1038/s413...
#CancerImmunotherapy
@melanomafocus.bsky.socialWe’re excited to have Professor Ricky on board and look forward to the knowledge and patient-centered perspective he’ll bring to Melanoma Focus.
Welcome, Ricky! đź’™
@ajhgnews.bsky.social🧬 New from @rohit-thakur.bsky.social et al!
đź“„Functional characterization of the 9q34.13 locus identifies RAPGEF1 as a candidate gene modulating risk for #melanoma and nevi via RAS activation
@newsen.bsky.socialSkylineDx's Transition to Direct Commercial Model Boosts Access to Revolutionary Merlin™ CP-GEP Test #USA #San_Diego #SkylineDx #melanoma #Merlin_CP-GEP
@rossqsmith.bsky.socialHow much for a blowjob by #Melanoma or Natalie?
@robertlufkinmd.bsky.social
@oncoalert.bsky.socialThe OncoAlert🚨 #WeekinOncology Continues with #Melanoma and we are proud to introduce our Expert #OncoAlertAF colleague Dr. Mario Balsa🇪🇸 to give us his pick of the most interesting article of the week.
@cowcakes.bsky.socialSitting in waiting room at clinic to get an unwanted guest removed. I did not give Mel permission to move in, they must leave forthwith. Tell the rest of the Noma family they aren't welcome either.
@thebabaklab.bsky.socialMerck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma.
Link in the comments 👇
#ClinicalMondays #Melanoma #CancerVaccine #mRNA #Immunotherapy
@jamasurgery.comAmong patients undergoing wide excision for #Melanoma, compliance with new Commission on Cancer surgical documentation guidelines improved in 2023, including margin size, excision depth, and use of Commission on Cancer forms.
@thecancersurvivorsclub.comA personalised cancer vaccine moves another step closer. A late-stage trial of an mRNA vaccine tailored to each patient’s tumour has shown it can reduce the risk of melanoma returning or spreading.